TY - JOUR
T1 - Amylin in bone conservation current evidence and hypothetical Considerations
AU - Zaidi, Mone
AU - Shankar, Vijai S.
AU - Huang, Christopher L.H.
AU - Pazianas, Michael
AU - Bloom, Stephen R.
N1 - Funding Information:
The studies described were supported in part by grants to M.Z. from the Medical Research Council (UK), Arthritis and Rheumatism Council (UK), Leverhulme Trust (UK), and the Sandoz Foundation for Gerontological Research (Basel, Switzerland). The authors are grateful to Mr. W. Smith (Cambridge) for skilled assistance. C.L.-H. is grateful to the Royal Society for partial support.
PY - 1993/10
Y1 - 1993/10
N2 - Amylin, a 37-amino-acid long single-chain polypeptide, is structurally homologous to calcitonin and calcitonin gene-related peptide (CGRP). The peptide is secreted from pancreatic β cells and is thought to have an anti-insulin action. Here, we review the recently described effects of amylin on calcium homeostasis and discuss its possible role in bone conservation. Amylin is a potent hypocalcemic and antiresorptive peptide. Studies using isolated osteoclasts have revealed that amylin inhibits cell motility (Q effect), without affecting cell spread area or elevating cytosolic [Ca2+]. Thus, amylin action is similar to that of calcitonin, but lower in potency. Lower circulating concentrations of amylin in type-1 diabetes may cause the bone loss associated with this condition.
AB - Amylin, a 37-amino-acid long single-chain polypeptide, is structurally homologous to calcitonin and calcitonin gene-related peptide (CGRP). The peptide is secreted from pancreatic β cells and is thought to have an anti-insulin action. Here, we review the recently described effects of amylin on calcium homeostasis and discuss its possible role in bone conservation. Amylin is a potent hypocalcemic and antiresorptive peptide. Studies using isolated osteoclasts have revealed that amylin inhibits cell motility (Q effect), without affecting cell spread area or elevating cytosolic [Ca2+]. Thus, amylin action is similar to that of calcitonin, but lower in potency. Lower circulating concentrations of amylin in type-1 diabetes may cause the bone loss associated with this condition.
UR - https://www.scopus.com/pages/publications/0027358334
U2 - 10.1016/1043-2760(93)90095-V
DO - 10.1016/1043-2760(93)90095-V
M3 - Article
AN - SCOPUS:0027358334
SN - 1043-2760
VL - 4
SP - 255
EP - 259
JO - Trends in Endocrinology and Metabolism
JF - Trends in Endocrinology and Metabolism
IS - 8
ER -